ConductScience.org, home

Paper39338268

Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A "Real-Life" Observational Study.

De Corso E and 20 others. J Pers Med, 2024. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A "Real-Life" Observational Study. Papers, record 39338268. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39338268

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Sinonasal Outcomes Obtained after 2 Years of Treatment with Benralizumab in Patients with Severe Eosinophilic Asthma and CRSwNP: A "Real-Life" Observational Study.
PubMed
Journal
J Pers Med
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
2.12, provisional
iCite
Revised in PubMed
2024-09-30
PubMed

Authors21

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1De Corso EEugeniohttps://orcid.org/0000-0001-5761-7018
2Mele DADario Antoniohttps://orcid.org/0000-0002-0765-9233
3Rizzi AAngelahttps://orcid.org/0000-0002-6795-746X
4Spanu CCamilla
5Corbò MMarcohttps://orcid.org/0009-0005-7394-8630
6Pisciottano SSerenahttps://orcid.org/0009-0005-2487-1219
7Mastrapasqua RFRodolfo Francescohttps://orcid.org/0000-0002-3558-8081
8Baroni SSilviahttps://orcid.org/0009-0009-8528-7533
9Porru DPDavide Paolo
10De Maio GGabriele
11Rizzuti AAlberta
12Di Bella GAGiuseppe Alberto
13Ortolan AAugustahttps://orcid.org/0000-0002-3131-0939
14Bonini MMatteo
15Cefaloni FFrancescahttps://orcid.org/0009-0004-6929-0912
16Boccabella CCristina
17Lombardi FFrancesco
18Chini RRaffaella
19Caruso CCristianohttps://orcid.org/0000-0001-7631-029X
20Panfili MMarcohttps://orcid.org/0000-0003-2764-8854

Source PubMed

See all 21 authorsDownload CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References32

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129316300Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population.Int Forum Allergy Rhinol2018https://conductscience.org/library/papers/29316300PubMed
233595845Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial.Clin Exp Allergy2021https://conductscience.org/library/papers/33595845PubMed
336013200Sinonasal Biomarkers Defining Type 2-High and Type 2-Low Inflammation in Chronic Rhinosinusitis with Nasal Polyps.J Pers Med2022https://conductscience.org/library/papers/36013200PubMed
417021776Normative data for the "Sniffin' Sticks" including tests of odor identification, odor discrimination, and olfactory thresholds: an upgrade based on a group of more than 3,000 subjects.Eur Arch Otorhinolaryngol2007https://conductscience.org/library/papers/17021776PubMed
538849701Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan.Drugs2024https://conductscience.org/library/papers/38849701PubMed
632250875Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry.Respir Med2020https://conductscience.org/library/papers/32250875PubMed
732816558Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.Int J Immunopathol Pharmacol2020https://conductscience.org/library/papers/32816558PubMed
827609408
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
Lancet2016https://conductscience.org/library/papers/27609408PubMed
923021878Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.J Allergy Clin Immunol2013https://conductscience.org/library/papers/23021878PubMed
1038829175Outcome measures for chronic rhinosinusitis with nasal polyps.Rhinology2024https://conductscience.org/library/papers/38829175PubMed
1127609406
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet2016https://conductscience.org/library/papers/27609406PubMed
1236507741The EUFOREA pocket guide for chronic rhinosinusitis.Rhinology2023https://conductscience.org/library/papers/36507741PubMed
1338426234Eosinophil extracellular traps in eosinophilic chronic rhinosinusitis induce Charcot-Leyden crystal formation and eosinophil recruitment.Biosci Rep2024https://conductscience.org/library/papers/38426234PubMed
1430478909Antileukotrienes improve naso-ocular symptoms and biomarkers in patients with NARES and asthma.Laryngoscope2019https://conductscience.org/library/papers/30478909PubMed
1539064286Real-Life Clinical Outcomes of Benralizumab Treatment in Patients with Uncontrolled Severe Asthma and Coexisting Chronic Rhinosinusitis with Nasal Polyposis.J Clin Med2024https://conductscience.org/library/papers/39064286PubMed
1614713908Development of the asthma control test: a survey for assessing asthma control.J Allergy Clin Immunol2004https://conductscience.org/library/papers/14713908PubMed
1728530840Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.N Engl J Med2017https://conductscience.org/library/papers/28530840PubMed
1819767070The minimally important difference of the Asthma Control Test.J Allergy Clin Immunol2009https://conductscience.org/library/papers/19767070PubMed
1938266634Correlation between inflammatory biomarkers and disease control in chronic rhinosinusitis with nasal polyps.Int Forum Allergy Rhinol2024https://conductscience.org/library/papers/38266634PubMed
2032499305Minimal clinically important difference for asthma endpoints: an expert consensus report.Eur Respir Rev2020https://conductscience.org/library/papers/32499305PubMed

See all 32 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
42827160Real-world two-year outcomes of mepolizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting severe asthma.Eur Arch Otorhinolaryngol2026https://conductscience.org/library/papers/42827160PubMed
42646747Staphylococcus Aureus Toxins and Asthma: Pathophysiological Mechanisms, Clinical Relevance, and Therapeutic Implications in the Biologics Era.Toxins (Basel)2026https://conductscience.org/library/papers/42646747PubMed
42511972Recovery of Olfactory Function After Mepolizumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps: Influence of the Number of Surgeries.Biomedicines2026https://conductscience.org/library/papers/42511972PubMed
41903052Psychophysical Olfactory Outcomes After Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta-Analysis.Curr Allergy Asthma Rep2026https://conductscience.org/library/papers/41903052PubMed
41608597Global airways: a Danish nationwide real-life registry of biologic therapy for chronic rhinosinusitis with nasal polyps.Front Allergy2025https://conductscience.org/library/papers/41608597PubMed
41261303Restoring the Sense of Smell: A Systematic Review and Meta-Analysis of Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyps.Curr Allergy Asthma Rep2025https://conductscience.org/library/papers/41261303PubMed
40237828[Diagnosis and drug therapy of chronic rhinosinusitis].HNO2025https://conductscience.org/library/papers/40237828PubMed
40200389Benralizumab and the integrated management of co-morbid severe eosinophilic asthma with chronic rhinosinusitis with nasal polyps.Clin Transl Allergy2025https://conductscience.org/library/papers/40200389PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
IL5RA3568PubTator's text mininghttps://conductscience.org/library/genes/3568

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39338268

GET https://conductscience.org/api/papers/v1/39338268/authors?page=2